WHY NOW
Biotech FP&A was always broken. Now it matters.
For twenty years, biotech FP&A meant six-month implementations, $50K-100K of consulting, and a real model that still lived in Excel. That worked when AI meant spell-check.
Now your AI can read data, write scenarios, and build board decks — but only if the platform was built to speak its language. Exports, RAG pipelines, and crossed fingers don’t count.
Exigyn is the first FP&A platform built for that world, and the first built for biotech finance from the ground up.
THE PROCESS
Five steps from your existing model to a board-ready deck.
Everything biotech finance does, in the order you actually do it.
IN MOTION
A round trip in under a 60 seconds.
Your AI asks Exigyn. MCP delivers the answer. Excel writes it back — 47 line items, no exports.
READ
“What’s our Q4 burn?”
Your AI sees the live number — not a week-old export.
WRITE
“Model a 6-month push.”
Scenarios commit to the plan in real time.
PLAN
“Update the board deck.”
PowerPoint stays fresh. No copy-paste, no versioning.
Benefits
Built for biotech finance.
INTEGRATIONS
Integration at its finest
Leverage the full power of Exigyn within your favorite tools.
VS. THE ALTERNATIVES
The three things no legacy platform can match.
Adaptive, Anaplan, and Pigment were built for a pre-AI, pre-biotech world. Here’s what that costs you.
IN PRODUCTION
Real customers. Real R&D spend.
CLIENTS LIVE IN DAY ONE
R&D EXPENSE MANAGED
FAQs
Questions.
Subprocessors

Subprocessors

Subprocessors









